1. Inici
  2. Publicacions
  3. Involvement of the-420C > G RETN polymorphism in myocardial fibrosis in patients with hypertrophic cardiomyopathy

Involvement of the-420C > G RETN polymorphism in myocardial fibrosis in patients with hypertrophic cardiomyopathy

Data de publicació:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Hernández-Romero D
  • Orenes-Piñero E
  • García-Honrubia A
  • Climent V
  • Romero-Aniorte AI
  • Martínez CM
  • García-Bautista M
  • Martínez M
  • Feliu E
  • González J
  • Cánovas S
  • Valdés M

Grups d'Investigació

Abstract

AimsHypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy and fibrosis. HCM is an autosomal-dominant disease caused by more than 400 mutations in sarcomeric genes. Changes in nonsarcomeric genes contribute to its phenotypic heterogeneity. Cardiac fibrosis can be studied using late gadolinium enhancement (LGE) cardiac magnetic resonance imaging. We evaluated the potential role of two polymorphisms in nonsarcomeric genes on interstitial fibrosis in HCM. Materials and methodsTwo polymorphisms in nonsarcomeric genes [ACE (deletion of 287bp in the 16th intron) and RETN (-420C>G)] were analysed in 146 HCM patients. Cardiac fibrosis was assessed using LGE to determine the number of affected segments. ResultsAllelic frequencies in ACE and RETN polymorphisms were consistent with the Hardy-Weinbergequilibrium (both P>0.05). We found that the presence of the polymorphic allele in the -420C>G RETN polymorphism was independently associated with the number of affected segments of LGE (P=0.038). Increased circulating resistin concentration, measured by enzyme-linked immunosorbent assay, was associated with a higher degree of cardiac fibrosis. Myocardial fibrosis, assessed by Masson's trichrome staining, was associated with the -420C>G RETN polymorphism in 46 tissue samples obtained by septal myectomy (P=0.044). ConclusionsThe -420C>G RETN polymorphism was independently associated with the degree of cardiac fibrosis, assessed by LGE, in patients with HCM. In addition, there was an association between the polymorphism and the circulating resistin levels as well as with myocardial fibrosis in tissues obtained by myectomy. Investigating the physiological implication of the RETN polymorphism in HCM in combination with the use of imaging technologies might help to establish the severity of disease in patients with HCM.

Dades de la publicació

ISSN/ISSNe:
0954-6820, 1365-2796

JOURNAL OF INTERNAL MEDICINE  WILEY-BLACKWELL

Tipus:
Article
Pàgines:
50-58
PubMed:
25476756
Factor d'Impacte:
3,331 SCImago ℠
Quartil:
Q1 SCImago ℠

Cites Rebudes en Web of Science: 5

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • angiotensin-converting enzyme; fibrosis; hypertrophic cardiomyopathy; late gadolinium enhancement; resistin

Campos d'Estudi

Projectes associats

REDINSCOR

RD06/0003/1001 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2008

RED DE BIOBANCOS (BIOBANCOS)

RD09/0076/00021 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2010

REGISTRO MULTICÉNTRICO DE PACIENTES HOSPITALIZADOS POR INSUFICIENCIA CARDÍACA AGUDA (REDINSCOR II).

RD12/0042/0003 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013

RED DE TERAPIA CELULAR (TERCEL)

Investigador Principal: PILAR SEPÚLVEDA SANCHIS

RD12/0019/0025 . INSTITUTO DE SALUD CARLOS III; FUNDACION FORMACION E INVESTIGACIÓN SANITARIA MURCIA (IMIB); FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013

HECATOS. HEPATIC AND CARDIAC TOXICITY SYSTEMS MODELLING.

Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL

602156_HECATOS_PE_FP7-HEALTH-2013-INNOVATI . 2013

MECANISMOS MOLECULARES Y CELULARES DE LAS CELULAS MESENQUIMALES HUMANAS Y DE LAS CELULAS CARDIACAS RESIDENTES DEL ADULTO EN EL ENTORNO CARDIACO ISQUEMICO Y EL NICHO HEMATOPOYETICO.

Investigador Principal: PILAR SEPÚLVEDA SANCHIS

PI13/00414 . INSTITUTO DE SALUD CARLOS III . 2014

DESARROLLO Y VALIDACIÓN DE UN MODELO DE ISQUEMIA MIOCÁRDICA PRECOZ MEDIANTE ESPECTROMETRÍA DE MASAS.

Investigador Principal: BEGOÑA IGUAL MUÑOZ

APM-39/15 . 2015

ESTUDIO DE DURABILIDAD DEL TRIFECTA.

Investigador Principal: JOSÉ ANASTASIO MONTERO ARGUDO

CS-10-012-EU-TV . 2011

ESTUDIO DE LA TOXICIDAD EN PLASMA INDUCIDA POR AGENTES QUIMIOTERÁPICOS.

Investigador Principal: JOSÉ ANASTASIO MONTERO ARGUDO

CARDIOTOX CLÍNICO

Compartir la publicació